Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (511-520 of 706) with videos related to

Pageof 71
Sort By:
Lancet (London, England)|May 4, 2010
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Alexander Thompson, Pei Gao, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE studyAntonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
European Journal of Heart Failure|June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trialMuthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
Circulation|April 23, 2008
Impact of time of presentation on the care and outcomes of acute myocardial infarctionHani Jneid, Gregg C Fonarow, Christopher P Cannon, et al.
European Heart Journal|November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosisDharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
JAMA|October 4, 2012
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery diseaseSripal Bangalore, Gabriel Steg, Prakash Deedwania, et al.
Journal of the American Heart Association|April 18, 2020
Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance ProgramsJacob A Doll, Lisa A Kaltenbach, Kevin J Anstrom, et al.
European Heart Journal|April 19, 2018
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trialsHarsh B Golwala, Christopher P Cannon, Ph Gabriel Steg, et al.
The American Journal of Cardiology|February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Pageof 71

Showing results (511-520 of 706) with videos related to

Sort By:
Pageof 71
Lancet (London, England)|May 4, 2010
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies, Alexander Thompson, Pei Gao, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|April 17, 2014
Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE studyAntonio M Gotto, Uma Kher, Manash Shankar Chatterjee, et al.
European Journal of Heart Failure|June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trialMuthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
Circulation|April 23, 2008
Impact of time of presentation on the care and outcomes of acute myocardial infarctionHani Jneid, Gregg C Fonarow, Christopher P Cannon, et al.
European Heart Journal|November 13, 2012
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosisDharam J Kumbhani, P Gabriel Steg, Christopher P Cannon, et al.
JAMA|October 4, 2012
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery diseaseSripal Bangalore, Gabriel Steg, Prakash Deedwania, et al.
Journal of the American Heart Association|April 18, 2020
Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance ProgramsJacob A Doll, Lisa A Kaltenbach, Kevin J Anstrom, et al.
European Heart Journal|April 19, 2018
Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trialsHarsh B Golwala, Christopher P Cannon, Ph Gabriel Steg, et al.
The American Journal of Cardiology|February 16, 2010
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)Christopher P Cannon, Karen E Rhee, Robert M Califf, et al.
Circulation|June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trialKenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
Pageof 71